Please provide your email address to receive an email when new articles are posted on . The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ...
DelveInsight's “Persistent Corneal Epithelial Defects Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Persistent Corneal Epithelial Defects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results